Previously, Christmas et al. (35) demonstrated synergistic anti-tumor activity with the triple combination of entinostat, an anti-programmed cell death protein 1 (PD-1) antibody and a HER2-targeted antibody in HER2/neu transgenic breast cancer models, resulting in significant reduction in tumor size and improved survival. This evidence concerns the gene PDCD1 and breast cancer.